An observational study in Carcinoid Heart Disease, Neuroendocrine Tumors and Carcinoid Syndrome, sponsored by National Institute of Cardiology, Warsaw, Poland. Not yet recruiting at 1 site in Poland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-04.
Sponsored by National Institute of Cardiology, Warsaw, Poland · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Neuroendocrine Tumors with a site in Poland — 4 open to participants now, 6 under way, 3 of them phase 3. Neuroendocrine Tumors · Poland.
Among the 22 studies in Neuroendocrine Tumors with a site in Poland, this one is one of 2 that started in 2026, is one of 7 observational ones, and was the 21st registered.
544 studies on the registry are indexed under Neuroendocrine Tumors; 136 are open to participants now.
Browse Neuroendocrine Tumors studies →4 of the 22 studies in Neuroendocrine Tumors with a site in Poland are open now. Recruiting first, the newest first:
Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz · Sites in Poland, United States, Brazil and 6 more countries
Ages 18+
Exelixis · Sites in Poland, United States, Australia and 15 more countries
Ages 18+
Turning Point Therapeutics, Inc. · Sites in Poland, United States, Australia and 16 more countries
Ages 12+
A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →
Of the 111 Neuroendocrine Tumors studies recruiting now, 72 (65%) set no upper age limit and 17 (15%) stop at 75 or younger; 12 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 7 · Phase 3 6 · Phase 4 2
First in 2004; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 120 is below the median of 134 across 130 observational studies indexed under Neuroendocrine Tumors.
Median enrollment 141 across the 15 interventional studies, 100 across the 7 observational. Of the 12 that completed or were terminated, 7 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 22 have an industry lead sponsor. The 10 most frequent:
National Institute of Cardiology, Warsaw, Poland is the lead sponsor of 54 studies on the registry; 12 are open to participants now.
National Institute of Cardiology, Warsaw, Poland has 1 study filed under Neuroendocrine Tumors — fewer than ten, so there is no comparison to draw.
3 of the studies in Neuroendocrine Tumors with a site in Poland that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07087054Phase 3Crinetics Pharmaceuticals Inc.Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen | 2027-08 |
| NCT07903532Instituto de Investigación Sanitaria de la Fundación Jiménez DíazMulticenter Study for External Validation of the TB-NET Score | 2027-03 |
| NCT07450287National Institute of Cardiology, Warsaw, PolandCardioNETPOL National Registry of Carcinoid Heart Disease | 2027-06-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 22 studies in Neuroendocrine Tumors with a site in Poland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Carcinoid tumors are neuroendocrine tumors (NETs), most commonly originating from the gastrointestinal tract, that may secrete bioactive substances such as serotonin. Persistent exposure to these mediators can lead to carcinoid syndrome and, in up to 50% of patients, carcinoid heart disease (CHD). CHD is characterized by fibrotic degeneration of cardiac valves, predominantly right-sided, resulting in progressive valvular dysfunction and a significant increase in mortality.
The mechanisms underlying selective cardiac involvement and predictors of disease progression remain incompletely understood. In addition, optimal timing and selection of surgical versus transcatheter valve interventions, particularly in high-risk patients, require further clarification.
This multicenter, retrospective observational registry aims to identify and characterize patients with carcinoid heart disease and at least moderate valvular involvement. CHD is defined by confirmed neuroendocrine tumor, echocardiographic evidence of ≥ moderate valvular disease with features of fibrosis, elevated NT-proBNP (>260 ng/L), and histopathological confirmation when available.
Approximately 100-120 consecutive patients will be enrolled over 12 months. Standardized data collection will include detailed echocardiographic assessment, demographic and clinical characteristics, cardiovascular risk factors, comorbidities, tumor features, oncological treatment history, and cardiac management strategies.
The primary objective is to describe the clinical profile and management of patients with CHD in a real-world multicenter setting. Secondary objectives include identifying factors associated with advanced valvular dysfunction and evaluating eligibility and outcomes of transcatheter valve therapies. The registry is expected to improve risk stratification and support clinical decision-making in carcinoid heart disease.
Carcinoid tumors are well-differentiated neuroendocrine neoplasms (NETs) capable of secreting vasoactive and fibrogenic substances, including serotonin, tachykinins, histamine, and prostaglandins. Persistent exposure to these mediators, particularly in the presence of hepatic metastases bypassing first-pass metabolism, may lead to the development of carcinoid syndrome and, in a substantial proportion of patients, carcinoid heart disease (CHD). Cardiac involvement is characterized by plaque-like fibrotic thickening of the endocardium, predominantly affecting right-sided heart valves, leading to leaflet retraction, reduced mobility, and progressive valvular regurgitation and/or stenosis. Over time, this process results in right ventricular volume overload, chamber dilation, heart failure symptoms, and reduced survival.
Although CHD represents a major determinant of prognosis in patients with carcinoid syndrome, important gaps remain in understanding its natural history, predictors of progression, and optimal management strategies. The incidence and severity of cardiac involvement vary considerably between individuals with similar oncologic profiles. Biomarkers such as NT-proBNP are widely used for screening and monitoring, but their integration with imaging findings and clinical variables in risk stratification requires further refinement. In addition, advances in oncological therapy have improved overall survival in NET patients, thereby increasing the clinical relevance of long-term cardiovascular complications.
Surgical valve replacement has traditionally been the standard treatment for advanced valvular dysfunction in CHD. However, many patients are at elevated operative risk due to metastatic disease burden, hepatic dysfunction, malnutrition, or other comorbidities. Emerging transcatheter valve therapies, including bicaval valve implantation and transcatheter tricuspid valve replacement or repair, offer potential alternatives for selected high-risk patients. Data regarding patient selection, anatomical suitability, procedural feasibility, and outcomes in the specific context of CHD remain limited.
This multicenter, retrospective, observational registry is designed to provide a comprehensive characterization of patients with carcinoid heart disease and at least moderate valvular involvement. Participating centers will identify consecutive eligible patients treated within predefined study periods to minimize selection bias. The registry reflects real-world clinical practice and does not mandate any additional diagnostic or therapeutic interventions beyond standard of care.
The study population consists of adult patients with a confirmed diagnosis of neuroendocrine tumor consistent with carcinoid tumor and evidence of carcinoid-related cardiac involvement. Cardiac involvement is established by echocardiographic documentation of at least moderate valvular dysfunction in conjunction with morphological features typical of fibrotic degeneration. Elevated NT-proBNP levels are required to support the presence of hemodynamic significance. In patients undergoing cardiac surgery, histopathological confirmation of carcinoid-related fibrosis will be recorded when available.
A standardized data collection framework will be applied across centers. Baseline demographic data include age, sex, body mass index, and relevant cardiovascular risk factors. Comorbid conditions such as hypertension, diabetes mellitus, chronic kidney disease, chronic liver disease, and prior cardiovascular events will be documented. Functional status will be assessed using available clinical classifications, including New York Heart Association (NYHA) class where recorded.
Comprehensive echocardiographic data will form a core component of the registry. Parameters to be collected include qualitative and quantitative assessment of tricuspid and pulmonary valve morphology and function, evaluation of left-sided valves when involved, right and left ventricular dimensions and systolic function, atrial size, inferior vena cava dimensions, and estimation of pulmonary artery pressures. When available, advanced imaging modalities (e.g., three-dimensional echocardiography or cardiac magnetic resonance imaging) will be documented, but their use is not mandated by the protocol.
Oncological variables will include primary tumor location, histopathological grade (if available), presence and distribution of metastases (hepatic, lymph node, bone, cardiac, or other), biochemical activity, and prior or ongoing systemic therapies. These may include somatostatin analogs, targeted therapies, peptide receptor radionuclide therapy, chemotherapy, and surgical resection of the primary tumor or metastases. Temporal relationships between oncological diagnosis, onset of carcinoid syndrome, and detection of cardiac involvement will be analyzed when data permit.
Cardiac management strategies will be recorded in detail. This includes medical therapy for heart failure, timing and type of surgical valve interventions, and the use of transcatheter approaches. For patients evaluated for transcatheter procedures, anatomical considerations, procedural planning parameters, and heart team decisions will be documented where available. Procedural outcomes, in-hospital course, and short-term follow-up data will be collected in accordance with local documentation standards.
The primary objective of the registry is descriptive: to define the clinical, echocardiographic, and oncological profile of patients with moderate to severe carcinoid heart disease in a contemporary, multicenter cohort. Secondary objectives include identification of clinical and imaging features associated with advanced right ventricular dysfunction, exploration of factors associated with referral for surgical versus transcatheter intervention, and assessment of early clinical outcomes following different management strategies.
Where longitudinal data are available, follow-up analyses will evaluate survival, heart failure progression, need for repeat interventions, and changes in functional status. A predefined subgroup analysis will focus on patients undergoing transcatheter valve therapies to assess feasibility, safety, and short- to mid-term effectiveness in this specific population.
Data will be anonymized at the site level before central aggregation. Each participating center will obtain appropriate approval from its institutional ethics or bioethics committee in accordance with national regulations. Given the retrospective and observational nature of the registry, no study-specific interventions are performed, and patient management remains entirely at the discretion of the treating physicians.
By systematically collecting and analyzing real-world data from multiple centers, this registry aims to enhance understanding of carcinoid heart disease, improve risk stratification, and support evidence-based decision-making regarding timing and type of valvular intervention. The results are expected to inform future prospective studies and contribute to the development of interdisciplinary care pathways integrating cardiology and oncology expertise in the management of this complex condition.
The study population consists of adult patients with carcinoid heart disease who are evaluated and treated at multiple tertiary cardiology and oncology centers across Poland, including the National Institute of Cardiology. Patients included in this registry represent a real-world, multicenter cohort of individuals with neuroendocrine tumors complicated by moderate to severe valvular heart disease. Data are collected retrospectively from consecutive patients meeting eligibility criteria, reflecting standard clinical practice and management of cardiac and oncologic care. The population includes both patients managed conservatively and those considered for surgical or transcatheter valve interventions.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This study is a multicenter, retrospective, observational registry of patients with carcinoid heart disease. The "intervention" consists of systematic collection and analysis of clinical, echocardiographic, and laboratory data, including demographic characteristics, cardiovascular risk factors, tumor features, metastatic status, and prior or planned cardiac and oncologic treatments. Detailed echocardiographic assessment of valve structure and function, chamber dimensions, and ventricular performance will be performed. The registry also identifies patients potentially eligible for transcatheter valve interventions. No experimental treatment is administered; all patient management follows standard clinical practice.
Characterization of patients with carcinoid heart disease
Characterization of patients with carcinoid heart disease defined as: presence of neuroendocrine tumor with hepatic metastases, echocardiographic evidence of right-sided valvular disease (tricuspid and/or pulmonary valve involvement), and biochemical evidence of serotonin excess (elevated urinary 5-HIAA or serum serotonin)
Time frame: At baseline (time of registry enrollment or most recent echocardiogram)
Identification of patients eligible for transcatheter valve interventions
Identification of candidates for transcatheter tricuspid or pulmonary valve replacement/repair among patients with carcinoid heart disease, assessed by echocardiography, CT-based anatomical evaluation and multidisciplinary Heart Team decision
Time frame: Baseline
Assessment of clinical factors associated with advanced valvular dysfunction
Identification of clinical factors associated with advanced valvular dysfunction in carcinoid heart disease, assessed by urinary 5-HIAA level (µmol/24h), NT-proBNP (pg/mL) and NYHA functional class
Time frame: Baseline
Assessment of echocardiographic factors associated with advanced valvular dysfunction
Identification of echocardiographic factors associated with advanced valvular dysfunction in carcinoid heart disease, assessed by tricuspid regurgitation grade and pulmonary valve function on transthoracic echocardiography
Time frame: Baseline
Plan to share: Yes — Individual participant data (IPD) will be entered into a secure electronic case report form (eCRF) provided by the scientific platform of the Polish Cardiac Society (Polskie Towarzystwo Kardiologiczne). All patient data will be fully anonymized before entry to protect privacy. The eCRF will be accessible to all participating centers. De-identified datasets may be shared with qualified researchers upon reasonable request, following approval by the registry steering committee and local ethics boards, in compliance with applicable national and institutional regulations.
Supporting information: Study protocol, Statistical analysis plan
Time frame: June 2026 - June 2027
Access criteria: Access to de-identified individual participant data (IPD) and supporting information (study protocol and statistical analysis plan) will be granted to qualified researchers upon reasonable request. Requests will be reviewed and approved by the registry steering committee and relevant local ethics boards. Approved researchers will have access to anonymized clinical, echocardiographic, laboratory, and treatment data through secure transfer or controlled access via the eCRF platform provided by the scientific platform of the Polish Cardiac Society. Data use will be governed by a data use agreement specifying conditions for confidentiality, publication, and compliance with applicable national and institutional regulations.
No publications or documents are linked to this record.
Start is estimated for Jun 2026; primary completion for Jun 2027, 12 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
National Institute of Cardiology, Warsaw, Poland